

Final Announcement

Please take note of the agenda for the upcoming

BBS
Basler Biometric Section

New developments in HTA, adaptive designs and Multiplicity – in remembrance of Willi Maurer BBS Spring Seminar

➔ April 17, 2018 from 9:00-17:00
Novartis Auditorium, Fabrikstrasse 15

The Seminar fee is 100 CHF for industry and free for all others
Please register by sending an email in advance to fred.sorenson@xcenda.com
Registration will close by Friday, April 13, 2018

Agenda

- | | |
|----------------------|--|
| 08:30 – 9:00 | Registration |
| 09:00 – 9:10 | Welcome
Uli Burger, BBS President |
| 9:00-12:40 | New developments in HTA |
| 9:10-10:40 | First Session: New developments in HTA (I)
Confirmed speakers are Jason Wang, Susan Edwards and Christoph Gerlinger |
| 10:40 – 11:10 | Coffee break |
| 11:10 – 12:40 | Second Session: New developments in HTA (II)
Confirmed speakers are Tim Friede and Carsten Schwenke |
| 12:40 – 13:30 | Lunch |
| 13:30 - 17:00 | In remembrance of Willi Maurer:
New developments in adaptive designs multiplicity adjustments |
| 13:30 – 14:30 | Third Session: Adaptive designs
Confirmed speakers are Tim Friede and Amy Racine |
| 14:30 – 15:00 | Coffee break |
| 15:00 – 16:30 | Fourth Session: Multiplicity corrections
Confirmed speakers are Martin Posch and Marcel Wolbers
Panel discussion with all Speakers |
| 16:30 – 17:00 | In remembrance of Willi Maurer
Amy Racine, Ekkehard Glimm and Uli Burger |
| 17:00 | Apero in remembrance of Willi Maurer |



Program

- 08:30 – 9:00** **Registration**
- 09:00 – 9:10** **Welcome**
Uli Burger, BBS President
- 9:00-12:40** **New developments in HTA**
- 9:10-10:40** **First Session: New developments in HTA (I)**
Session chair: Fred Sorenson (Xcenda)
Jason Wang, Chrissie Fletcher, (Celgene&Amgen) - *Estimands and HTA*
Christoph Gerlinger (Bayer) - *Comparing the EQ-5D-5L Utility Index based on value sets of different countries – Impact on the interpretation of clinical study results*
Susan Edwards (Hoffmann-La Roche) – *Whose perspective? Implications on cost-effectiveness modelling of differences between country value sets (a case study)*
- 10:40 – 11:10** **Coffee break**
- 11:10 – 12:40** **Second Session: New development in HTA (II)**
Session chair: Juliane Schäfer (Hoffmann- La Roche)
Carsten Schwenke - *Real-world evidence and HTA - experiences with IQWiG*
Tim Friede - *Drug safety and HTA*
Panel discussion with all speakers
- 12:40 – 13:30** **Lunch**
- 13:30 - 17:00** **In remembrance of Willi Maurer:**
New developments in adaptive designs multiplicity adjustments
- 13:30 – 14:30** **Third Session: Adaptive designs**
Session chair: Achim Guettner
Tim Friede (University of Göttingen) - *The rise of adaptive designs in the pharmaceutical industry*
Amy Racine, Anthony D’Amelio, Tomas Haas, Emmanuel Zuber (Novartis) - *Adaptive Phase 2 Open Platform Design in Metastatic Melanoma*
- 14:30 – 15:00** **Coffee break**
- 15:00 – 16:30** **Fourth Session: Multiplicity adjustments**
Session chair: Uli Burger
Martin Posch (University of Vienna) - *Mastering Multiplicity in Drug Development: Shortcuts, Graphs and Multiple Testing*
Marcel Wolbers, Kaspar Rufibach and Daniel Sabanes Bove (Hoffmann-La Roche) - *Pre-planned subgroup analysis within a group-sequential design for a time-to-event endpoint*
Panel discussion with all speakers
- 16:30 – 17:00** **In remembrance of Willi Maurer**
Amy Racine, Ekkehard Glimm and Uli Burger
In remembrance of Willi
- 17:00** **Apéro in remembrance of Willi**